The only thing that matters is IPIX's follow-up to releasing their data. Remember, they've released Brilacidin ABSSSI, IBD, and Oral Mucositis data which in all three phase 2 and phase 2b trials they claimed were groundbreaking for patients worlwide' and 'discussions were under way' for deals...and 10 years on, the CEO executed a deal for $100K less than his annual salary. SO, if there is great covid data, the important thing is the FOLLOW-UP in $$$$s to that data, not just the data. Let history and that reality sit for a while. It's not like there isn't a GIGANTIC unment need in IBD or OM etc (in the BILLIONS. Expectation is largely baked into share price already. The follow-up is where the share price explodes. Take their Alfasigma deal of the century: the share price DROPPED 18% on deal announcement PR, and we are still 'living in an oral mucositis world'.
The company needs to 1) release exceptional data (not just 'good' data, eg 'there's some signal there, and this is worth some funding to continue to explore maybe as a nebulized product etc completed---which becomes a multi-year formulation project, NOT an overnight fast EUA approval'. no, the data needs to be exceptional. 2) if the data is exceptional, they then need to strike an exceptionally lucrative and smart deal. If the data is exceptional, even my cat could execute a good deal. But, if the data is 'good' or 'okay' with a spin, then the record may keep spinning like it has for years with post phase 2 brilacidin follow-up.
thankfully, Locust Walk, is on board, which has a great track record of deal making. Otherwise, wow, god help us all.
Market Data 
Markets 
AI
